Consistent with what we observed previously in the PHF14 knockdown neuroblastoma SHSY-5Y cells, the primary neurocytoma cells exhibited greater sensitivity to Sunitinib treatment (5 μM, 0.1 ± 0.01 vs. 1.0 ± 0.04, p < 0.005) when compared to the MAPK/ERK or AMPK/AKT inhibitors MEK-162 and Metformin (Figure 4D). This evidence concerns the gene MAP2K7 and central neurocytoma.